In conclusion, we demonstrate that the presence of plasma IL-23 and circulating IL-17A+IFNγ+ ex-Th17 cells have the potential to predict disparate outcomes for anti-TNF therapy in RA. The gene discussed is IL37; the disease is rheumatoid arthritis.